Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73)
These small molecules are novel nucleotide derivatives, containing either a purine or pyrimidine nucleobase, that competitively block the enzyme CD73, also known as ecto-5'-nucleotidase. This enzyme converts extracellular AMP (not a potent activator of adenosine receptors) to adenosine (the native activator of 4 subtypes of adenosine receptors. CD73 inhibitors are being used, in clinical trials and preclinical research, in conjunction with cancer immunotherapy. CD73 is upregulated around tumors to produce excessive adenosine, and blocking this enzyme greatly reduces immunosuppressive adenosine in the tumor microenvironment. Therefore, combined therapy is expected to be more effective than cancer immunotherapy alone. Pharma companies are working on blockers, either small molecules or monocolonal antibodies, to block CD73 for application to cancer therapy, and some have already entered clinical trials.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Inventors:
Kenneth Jacobson (NIDDK) ➽ more inventions...
Christa Mueller
Anna Junker
Intellectual Property:
US Application No. 62/719,492
PCT Application No. PCT/US2019/046931
Publications:
Junker, A., et al Structure-Activity relationship of purine and pyrimidine nucleotides as ecto-5'-nucleotidase (CD73) inhibitors., J. Med. Chem., 2019, 62:3677-369
Collaboration Opportunity:
The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73). For collaboration opportunities, please contact Betty B. Tong, Ph.D. at tongb@mial.nih.gov
Licensing Contact:
Betty Tong, Ph.D.
Email: tongb@niddk.nih.gov
Phone: 301-451-7836
OTT Reference No: E-132-2018-0
Updated: Aug 9, 2019